Abstract Body

Background

With widespread use of oral and injectable PrEP, accurate HIV testing remains critical. Recent evidence has questioned the utility of HIV RNA screening at PrEP visits, due to its association with increased false positive results. We sought to characterize the frequency and correlates of false positive HIV test results within one of the largest HIV testing and PrEP prescribing programs in the United States.

Methods

We analyzed all HIV testing events at Howard Brown Health between September 22, 2022 and August 31, 2025. Testing modalities included point-of-care (POC) rapid antibody/antigen tests, laboratory-based 4th generation assays, and HIV RNA assays. False positives were defined as any initially reactive test not confirmed by supplemental assays or follow-up testing. We excluded recalled test lots and repeat false positive episodes in the same patient; all false positives were confirmed by chart review. Logistic regression assessed associations between PrEP use/type, testing modality, and false positive results.

Results

Among 104,088 HIV testing events during the study period, 96,691 (92.9%) included laboratory-based 4th generation assays, 32,962 (31.7%) included POC tests, and 7,843 (7.5%) included RNA tests.  Overall, 64,016 (61.5%) tests occurred among PrEP users. A total of 156 false positives (0.15%) were identified. By test type, false positives were most common with laboratory-based 4th generation assays (145/156; 93%). Among PrEP users, injectable PrEP was associated with a significantly lower frequency of false positive HIV results compared to oral PrEP (0.06% vs 0.15%; p=0.04).  Of the 4,856 RNA tests among injectable PrEP users, no false positives occurred.  There were no other statistically significant associations between PrEP use, PrEP type, or testing modality and false positive results.

Conclusions

False positive HIV test results were uncommon across one of the largest urban community health center–based PrEP programs in the United States. No RNA false positives were observed among individuals using injectable PrEP. Continued surveillance is needed to optimize HIV diagnostic algorithms in the context of expanding oral and long-acting PrEP use.